Effects of The Novel Endocannabinoid Uptake Inhibitor, LY2183240, on Fear-Potentiated Startle and Alcohol-Seeking Behaviors in Mice Selectively Bred for High Alcohol Preference by Powers, Matthew S et al.
Purdue University
Purdue e-Pubs
Department of Psychological Sciences Faculty
Publications Department of Psychological Sciences
2010
Effects of The Novel Endocannabinoid Uptake
Inhibitor, LY2183240, on Fear-Potentiated Startle
and Alcohol-Seeking Behaviors in Mice Selectively









Follow this and additional works at: http://docs.lib.purdue.edu/psychpubs
Part of the Psychiatry and Psychology Commons
This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.
Recommended Citation
Powers, Matthew S.; Barrenha, G. D.; Mlinac, N. S.; Barker, Eric L.; and Chester, Julia, "Effects of The Novel Endocannabinoid Uptake
Inhibitor, LY2183240, on Fear-Potentiated Startle and Alcohol-Seeking Behaviors in Mice Selectively Bred for High Alcohol
Preference" (2010). Department of Psychological Sciences Faculty Publications. Paper 71.
http://dx.doi.org/10.1007/s00213-010-1997-2
Effects of The Novel Endocannabinoid Uptake Inhibitor, LY2183240, on Fear-Potentiated 
Startle and Alcohol-Seeking Behaviors in Mice Selectively Bred for High Alcohol 
Preference 
 
M.S. Powersa, G.D. Barrenhaa, N.S. Mlinaca, E.L. Barkerb, J.A. Chestera* 
 
Department of Psychological Sciencesa 
Department of Medicinal Chemistry and Molecular Pharmacologyb 
Purdue University, West Lafayette, IN 47907 
 
Acknowledgements:  Supported by AA016843 to JAC.  We are grateful to Dr. Nicholas J. 
Grahame for providing the breeders for the HAP and LAP mice and to Laran Coon for technical 
assistance.  We also thank Eli Lilly and Co. for generously donating the LY2183240 used in 
Experiments 1 and 2.  The experiments described herein comply with the current laws of the 
Unites States of America.  The authors do not have any financial conflicts of interest to report. 
 
*Corresponding author: Julia A. Chester, Ph.D. 
Purdue University  
Psychological Sciences 
703 Third Street 
West Lafayette, IN 47907-2081 
Phone:  765-494-6863 
FAX:  765-496-1264 
E-mail:  jchester@psych.purdue.edu 
2 
Abstract 
Rationale  Alcohol-use disorders often occur together with anxiety disorders in humans which 
may be partly due to common inherited genetic factors.  Evidence suggests that the 
endocannabinoid system (ECS) is a promising therapeutic target for the treatment of individuals 
with anxiety and/or alcohol-use disorders.   
Objectives  The present study assessed the effects of a novel endocannabinoid uptake 
inhibitor, LY2183240, on anxiety- and alcohol-seeking behaviors in a unique animal model that 
may represent increased genetic risk to develop co-morbid anxiety and alcohol-use disorders in 
humans.  Mice selectively bred for high alcohol preference (HAP) show greater fear-potentiated 
startle (FPS) than mice selectively bred for low alcohol preference (LAP).  We examined the 
effects of LY2183240 on the expression of FPS in HAP and LAP mice and on alcohol-induced 
conditioned place preference (CPP) and limited-access alcohol drinking behavior in HAP mice.   
Results  Repeated administration of LY2183240 (30 mg/kg) reduced the expression of FPS in 
HAP but not LAP mice when given prior to a second FPS test 48 hrs after fear conditioning.  
Both the 10 and 30 mg/kg doses of LY2183240 enhanced the expression of alcohol-induced 
CPP and this effect persisted in the absence of the drug.  LY2183240 did not alter limited-
access alcohol drinking behavior, unconditioned startle responding, or locomotor activity.   
Conclusions  These findings suggest that ECS modulation influences both conditioned fear 
and conditioned alcohol reward behavior.  LY2183240 may be an effective pharmacotherapy for 
individuals with anxiety disorders, such as post-traumatic stress disorder, but may not be 
appropriate for individuals with co-morbid anxiety and alcohol-use disorders.    
 
  




Alcohol abuse and alcoholism are common alcohol-use disorders that frequently occur 
together with anxiety disorders (Kessler et al. 1997; Kushner et al. 1990), termed co-morbidity.    
One hypothesis put forth to account for the co-morbid expression of alcohol-use and anxiety 
disorders is that there are common factors, such as inherited genetic factors, that increase the 
risk for developing both disorders.  This hypothesis is supported by several studies in humans in 
which alcoholism has been found to occur more frequently in individuals with a family history of 
anxiety disorders (Maier et al., 1993; Munjack and Moss, 1981) and anxiety disorders occur 
more frequently in individuals with a family history of alcoholism (Merikangas et al. 1985; 1998).   
A growing body of evidence suggests that the endocannabinoid system (ECS) plays an 
important role in regulating anxiety- and alcohol-related behaviors and may represent an 
important drug target for the treatment of anxiety- and alcohol-use disorders.  Genetic and 
pharmacological studies support a prominent role for the ECS in regulating both anxiety- 
(Pacher et al. 2006) and alcohol-related behaviors (Hungund and Basavarajappa, 2004).  For 
example, mice with genetic deletion (knockout) of cannabinoid (CB) 1 receptors exhibit more 
anxiety-related behavior than wild-type mice in both unconditioned and conditioned anxiety 
models (see reviews by Lafenêtre et al. 2007; Viveros et al. 2005).  Direct agonists of the CB1 
receptor and drugs that increase brain endocannabinoid (EC) levels (e.g., EC transport 
inhibitors) produce anxiolysis in several models of unconditioned anxiety and facilitate extinction 
of conditioned anxiety responses in fear conditioning models (Lutz, 2007; Pamplona et al. 2008; 
Resstel et al. 2008).   
With regard to alcohol-seeking behavior, genetic deletion and pharmacological blockade of 
CB1 receptors reduces alcohol intake (e.g., Cippitelli et al. 2005; Colombo et al. 2007; Hansson 
et al. 2007; Hungund et al. 2003), whereas enhancing ECS activity, either through CB1 receptor 
activation (Gallate et al. 1999) or inhibition of EC breakdown (Hansson et al. 2007) often 
increases alcohol intake in rodents.  However, the EC uptake and metabolism inhibitor AM404 
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has been shown to reduce alcohol intake in rats, an effect that was not mediated through CB 
receptors (Cippitelli et al. 2007).  There is also some evidence indicating that alterations in ECS 
function may be a neurobiological mechanism that influences alcohol preference in rodents with 
a genetic propensity toward high or low alcohol consumption (Cippitelli et al. 2005; Hansson et 
al. 2007; Hungund and Basavarajappa, 2000).  Finally, there are two published reports showing 
that CB1 receptor knockout mice display weaker conditioned place preference (CPP) to alcohol 
compared to wild-type controls (Houchi et al. 2005; Thanos et al. 2005), suggesting that CB1 
receptors normally modulate the rewarding effects of alcohol.   
Post-traumatic stress disorder (PTSD) is one anxiety disorder that has a particularly high 
prevalence among people with alcohol-use disorders (Adams et al. 2006; Brady et al. 2000; 
Breslau et al. 1997; Engel et al. 1999; Ikin et al. 2004; Kessler et al. 1995; 1996).  The fear-
potentiated startle (FPS) paradigm, where startle reactivity is enhanced by states of anxiety or 
fear (Davis, 1990), may be a relevant model for PTSD because both humans and rodents show 
FPS after exposure to trauma or stress-related stimuli (Grillon, 2002) and pharmaceutical drugs 
used clinically to treat anxiety disorders reduce FPS (Hijzen et al. 1995).  We have recently 
shown that mice selectively bred for high alcohol preference (HAP) display greater FPS than 
mice selectively bred for low alcohol preference (LAP) (Barrenha and Chester, 2007).  These 
findings suggest that common genes may influence the propensity to develop learned fear-
related behavior and alcohol drinking behavior in this mouse model and support the idea that 
co-morbidity between alcohol-use and anxiety disorders such as PTSD in humans may have a 
genetic basis (Maier et al. 1993; Merikangas et al. 1985; 1998; Munjack and Moss, 1981).  
Selectively bred HAP mice may represent a unique genetic animal model to identify effective 
pharmacotherapies for anxiety, alcohol-use disorders, or both.   
 The purpose of the present study was to assess the effects of a novel EC uptake 
inhibitor, LY2183240, on FPS and alcohol-seeking behaviors in HAP mice.  Little is known about 
the behavioral effects or pharmacological actions of drugs that block the uptake and/or 
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degradation of ECs.  LY2183240, like the fatty acid amide hydrolase (FAAH) inhibitor URB597, 
potently inhibits FAAH activity by carbamylation of the enzyme’s serine nucleophile.  However, 
unlike URB597, LY2183240 is not selective for FAAH as multiple other serine hydrolases are 
inactivated by LY2183240 in vivo (Alexander and Cravatt, 2006).  Alcohol-seeking behavior was 
assessed using alcohol-induced CPP and a limited-access drinking paradigm.  LY2183240 has 
been shown to produce dose-dependent analgesia and associated increases in anandamide 
(AEA) in rats (Moore et al. 2005) and inactivate FAAH in mice (Alexander and Cravatt, 2006).  
However, this is the first study to examine the effects of LY2183240 on anxiety-related and 
motivated behaviors in an animal model.  Administration of LY2183240 was expected to reduce 
FPS, based on similar findings in prior studies where activation of the ECS decreased anxiety-
related behavior.  We also predicted that LY2183240 would enhance the expression of alcohol-
induced CPP and increase alcohol drinking behavior based on the majority of reports indicating 
that activation of the ECS enhances alcohol-seeking behavior.  
 
Materials and Methods 
Subjects 
Subjects were adult male and female HAP mice from replicate lines 1 and 2 and LAP 
mice from replicate line 1.  HAP and LAP lines were produced by mass selection from outbred 
HS/Ibg mice (Boulder, CO, USA) at the Indiana Alcohol Research Center (IARC) in Indianapolis, 
IN, USA (Grahame et al. 1999).  Subjects in the current study were alcohol naïve and were 
generated at Purdue University from HAP and LAP breeders obtained from the IARC.  Replicate 
1 HAP mice were from the 34th and 37th generation and replicate 2 HAP mice were from the 
27th, 29th, and 34th generation of selection for high alcohol preference.  LAP mice were 7th and 
8th generation offspring from generation 27 breeders maintained with relaxed selection.  Mice 
were between 62 and 103 days of age at the start of experimental procedures.   
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Mice were housed in polycarbonate cages (29.2 x 19.0 x 12.7 cm) with aspen wood 
shavings in groups of 2-4 per cage.  For the drinking study (Experiment 3), mice were 
acclimated to single housing for 7 days prior to the start of limited-access drinking.  Ambient 
temperature in the colony rooms ranged from 20.2-21.9ºC and animals had free-access to food 
(Rodent Lab Diet 5001, Purina Mills Inc., St. Louis, MO, USA) and water throughout the 
experiments.  Experimental procedures were conducted during the light phase of a 12:12 
light/dark cycle.    
The experiments were carried out in accordance with the principles of laboratory animal 
care and all procedures were approved by the Purdue Animal Care and Use Committee.   
 
Drugs   
For the place conditioning study, alcohol was diluted from a 95% (v/v) solution to a 
concentration of 20% (v/v) with physiological saline (0.9%) and was administered 
intraperitoneally (IP) in a dose of 2.0 grams per kilogram of body weight (g/kg) (0.06 g per 30 g 
body weight) and in an injection volume of 12.6 ml/kg.  For the drinking study, alcohol was 
diluted from a 95% (v/v) solution to a concentration of 10% with tap water.  LY2183240 was 
dissolved in DMSO (did not exceed 3.75%) and suspended in 1.0% 
carboxymethylcellulose/0.5% sodium lauryl sulfate/0.08% Tween 80 in distilled water and was 
administered in doses of 10 and 30 mg/kg (0.3 and 0.9 mg/30 g body weight, respectively).  
These doses of LY2183240 produced dose-dependent analgesia and associated increases in 
AEA in rats (Moore et al. 2005) and inactivated FAAH in mice (Alexander and Cravatt, 2006). 
 
Fear-potentiated Startle Apparatus 
FPS was assessed using two dark, sound-attenuated Coulbourn Instruments (Allentown, 
PA, USA) Animal Acoustic Startle System chambers, as previously described (Barrenha and 
Chester, 2007).  Startle stimuli consisted of 100 dB, 40 msec white noise bursts of varying 
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intensities (frequency range: 20 Hz-20 kHz).  Subjects’ startle responses were measured as the 
amount of force in grams exerted against a weight-sensitive platform during the 200 msec after 
the onset of each acoustic stimulus.  The force measurement does not include the subject’s 
bodyweight, which removes any variation in startle response magnitude that may be accounted 
for by individual differences.  A ventilating fan provided continuous 70-71 dB background noise.   
 
Place Conditioning Apparatus 
The place conditioning apparatus consisted of 8 identical open-top boxes enclosed in 
separate ventilated sound- and light-attenuating chambers, as previously described (Chester 
and Coon, 2010).  The floor of each box consisted of interchangeable halves with distinct floor 
textures (grid or hole).  Locomotor activity and side position (left or right) for each mouse was 
continuously monitored by the Hamilton-Kinder MotorMonitor program (Model HMM100, San 
Diego, CA, USA).   
 
Blood Alcohol Concentration (BAC) Analysis 
For the alcohol drinking study, approximately 0.05 ml of blood was collected from the 
submandibular vein into heparinized capillary tubes (Fisher Scientific, Pittsburgh, PA, USA).  
Blood samples were placed on ice, immediately centrifuged at 12,000 rpm, and plasma was 
extracted and frozen at –80 C until analyzed for BAC using an AM1 Analyzer (Analox 
Instruments, Lunenburg, MA, USA).  
 
Study Procedures 
Experiment 1: Effects of LY2183240 on the Expression of FPS 
Experiment 1 consisted of three separate experiments (1a-1c).  The purpose of 
Experiment 1a (n=66; 37 HAP male, 29 HAP female) was to assess the effects of LY2183240 
on the expression of FPS in HAP mice and was conducted in two matched replications.  
8 
Experiment 1b (n=48; 24 HAP male, 24 HAP female) was conducted to replicate the findings in 
Experiment 1a because average FPS responses in the vehicle-treated group in Experiment 1a 
were lower than that previously reported in HAP mice (Barrenha and Chester, 2007).  The 
purpose of Experiment 1c (n=31; 14 LAP male, 17 LAP female) was to assess the effects of 
LY2183240 on FPS in LAP mice.   
Mice received 60-min conditioning sessions and 55-min FPS test sessions, as previously 
described (Barrenha and Chester, 2007).  Briefly, the conditioning session began with 10 trials 
of 100 dB (40 msec) startle stimuli separated by a 2-min inter-trial interval (ITI) followed by 
twenty conditioning trials.  Each conditioning trial consisted of a 30-sec, 7 W light stimulus 
paired with a 0.5-sec, 0.8 mA footshock.  The FPS test session consisted of 36 total trials 
separated by a 2-min ITI and were presented randomly throughout the test session to avoid 
habituation to any single trial type.  Twelve of the trials were blank (no stimuli), 12 were noise 
alone (100 dB, 40 msec), and 12 were light (7 W, 30 sec) + noise (100dB, 40 msec).  On light + 
noise trials, the noise stimulus was presented immediately after the light stimulus ended.  Mice 
were tested for FPS twice: 24 and 48 hrs after the conditioning session.  Mice received an IP 
injection of either vehicle, 10 or 30 mg/kg LY2183240 30 min before each FPS test. 
 
Experiment 2:  Effects of LY2183240 on the Expression of Alcohol-induced CPP 
The place conditioning study involved one pre-conditioning preference test, eight 
conditioning sessions, and three post-conditioning preference tests.  Conditioning and 
preference tests were conducted on consecutive days except that a 2-day break separated the 
first four and second four conditioning sessions. 
HAP mice (n=90; 42 HAP male, 48 HAP female) were exposed to a Pavlovian 
differential place conditioning procedure, as previously described (e.g., Chester and Coon, 
2010).  On alternating days during conditioning, mice in the grid+ subgroup received an IP 
injection of alcohol (2.0 g/kg) immediately before a 5-min conditioning session on the grid floor.  
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These mice received saline before exposure to the hole floor on intervening days.  Conversely, 
mice in the hole+ subgroup received alcohol paired with the hole floor and saline paired with the 
grid floor.  Assignment of mice to experimental groups and conditioning subgroups was 
counterbalanced by litter of origin, order of exposure to alcohol or saline, order of exposure to 
the floor textures (grid or hole), floor position (left or right side of the box) during preference 
tests, and apparatus enclosure.   
For the pre-conditioning preference test, all mice received a saline injection immediately 
before being placed in the apparatus on a half grid/half hole floor for 60 min.  Three post-
conditioning preference tests were administered 24, 48, and 72 hrs after the final conditioning 
session.  Mice received an IP injection of either vehicle, 10 or 30 mg/kg LY2183240 30 min 
before the first two preference tests and a saline injection 30 min prior to the third preference 
test to assess whether any effects of LY2183240 on alcohol-induced CPP would be maintained 
in the absence of the drug.   
 
Experiment 3:  Effects of LY2183240 on Limited-access Alcohol Drinking 
 HAP mice (n=43; 23 HAP male, 20 HAP female) were exposed to a 2-hr limited-access 
drinking procedure.  Two days before the limited-access acquisition phase began mice were 
weighed and given IP saline injections to habituate them to handling and injection procedures.  
On days 1-6, standard water bottles were replaced for 2 hrs with two 25 ml graduated cylinders 
fitted with stainless steel sipper tubes.  One tube contained tap water and the other contained a 
10% v/v alcohol solution.  On these days mice were weighed 30 min before the start of the 2-hr 
drinking session but no injections were given.  On days 7-8, mice were weighed and received 
saline injections 30 min before the start of the 2-hr drinking session.  Based on the average 
alcohol intake on these 2 days, mice were assigned to drug treatment groups in a 
counterbalanced fashion.  On the drug testing days (days 9-10), mice received an injection of 
vehicle, 10 or 30 mg/kg LY2183240 30 min prior to the start of the 2-hr drinking session.  
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Immediately after the final fluid intake reading on the second drug testing day, a blood sample 
was taken from each mouse to assess BAC in all drug treatment groups.  Fluid intake was read 
to the nearest 0.5 ml once at 30 min after the start of, and again at the end of, the 2-hr drinking 
sessions.  Left/right bottle positions were alternated daily to avoid a possible positional 
preference.  The 2-hr drinking sessions occurred during the last 2 hrs of the light phase of the 
12:12 light/dark cycle. 
 
Statistical Analyses  
Acoustic startle responses for each mouse on the 12 noise-alone and light+noise trials 
were averaged.  FPS was analyzed using a proportional change score, termed % FPS, 
calculated with the following formula: [((average startle amplitude on light+noise trials - average 
startle amplitude on noise-alone trials)/average startle amplitude on noise-alone trials) x 100].  
The % FPS measure adjusts for individual and group differences in startle reactivity and is an 
accurate and sensitive measure of FPS (Risbrough et al. 2003; Walker and Davis, 2002).  Three 
mice were removed from Experiment 1 because their startle responses across all startle trials 
(including pre-training startle trials) did not reach the minimum startle response criterion of 11 
grams of force.   
Thirty-one HAP mice (15 male and 16 female) were excluded from Experiment 3 due to 
inconsistent alcohol intake behavior during the 2-hr limited-access acquisition phase.  Mice 
were excluded if they met either of the following two criteria: 1) no alcohol intake for 2 
consecutive days after the initial 3 days of limited-access exposure, or 2) no alcohol intake on 
either of the baseline limited-access days (where limited-access was preceded by saline 
injections).  Data points lost because of fluid spillage or that were deemed to be outliers were 
replaced with an average intake value, as previously described (Chester et al., 2008). There 
were 2 missing values and 3 valid outliers during the acquisition phase only.  
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Data were analyzed using analysis of variance (ANOVA) with the significance level set 
at p<0.05.  Between-group factors included Dose Group, Sex, Conditioning Subgroup (grid+ or 
hole+) and Study Replication (Experiment 1) and within-group factors included Test Day, Floor 
Type (grid or hole), Conditioning Session Type (alcohol or saline), Trial, Block (2-day drinking 
averages), or Time, where applicable.  Significant interactions were followed using lower-order 
one-way ANOVAs and Tukey’s multiple comparison tests (Keppel, 1991).  
 
Results 
Experiment 1: Effects of LY2183240 on the Expression of FPS 
Figure 1 shows data from the first and second FPS test in HAP mice.  During the first 
FPS test, there were no significant effects of LY2183240 on the expression of FPS.  However, 
during the second FPS test, the 30 mg/kg dose of LY2183240 significantly reduced the 
expression of FPS.   
Initial analysis of the data in HAP mice from Experiments 1a and 1b included Study 
Replication as a factor in the repeated-measures ANOVA (Study Replication x Dose Group x 
Sex x Test Day).  This analysis yielded a Dose Group x Test Day interaction [F(2,96)=3.8, 
p<0.05] but no interactions with Study Replication.  Follow-up one-way ANOVAs of Dose Group 
on each test day yielded a significant main effect of Dose Group on test day 2 only 
[F(2,111)=6.3, p<0.01].  Tukey’s post-hoc analyses of % FPS revealed significantly lower % 
FPS in mice treated with 30 mg/kg LY2183240 compared to the vehicle (p<0.01) and to the 10 





Analysis of data on noise-alone trials in HAP mice (Study Replication x Dose Group x 
Sex x Test Day ANOVA) indicated a Dose Group x Test Day interaction [F(2,96)=4.2, p<0.05] 
but follow-up one-way ANOVAs of Dose Group within each Test Day yielded no significant 
differences (data not shown).   These data indicate that the effect of LY2183240 on % FPS in 
HAP mice is not due to alterations in unconditioned startle responses.   
 Figure 2 shows data from the first and second FPS test in LAP mice (Experiment 1c).  
LY2183240 did not alter % FPS or unconditioned startle responses.  Analysis of % FPS and 
noise-alone startle data (Dose Group x Sex x Test Day ANOVAs) showed only main effects of 
Test Day for % FPS [F(1,25)=6.2, p<0.05; test 2 > test 1] and for noise-alone startle responses 





Experiment 2:  Effects of LY2183240 on the Expression of Alcohol-induced CPP 
Pre-test 
Mice spent on average more time on the grid floor (32.4±0.8 sec/min) vs. the hole floor 
(27.6±0.8 sec/min) during the 60-min pre-test.  Analysis of the raw time spent on the grid or hole 
floor [Dose Group x Sex x Floor Type x Time (first 30 and last 30 min) ANOVA] yielded a main 
effect of Floor Type [F(1,84)=8.0, p<0.01; grid > hole].  Data for all mice were transformed to 
time on CS+ floor and this variable was subjected to a Dose Group x Sex x Conditioning 
Subgroup x Time ANOVA which revealed a main effects of Time [F(1,78)=7.7, p<0.01] and 
Conditioning Subgroup [F(1,78) =6.3, p=0.01] due to mice in the hole+ subgroup spending less 
time on their CS+ floor (26.3±1.1 sec/min) then mice in the grid+ group (30.6±1.2 sec/min).  
Importantly, however, there were no main effects of Drug Group or interactions with this factor 
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indicating that time spent on the CS+ floor during both the first 30 and last 30 min of the pre-test 
was similar in all dose groups prior to the start of conditioning.  Mean (±SEM) activity counts 
during the pre-test were significantly higher during the first 30 min (77.6±1.2 counts/min) than 
the last 30 min of the pre-test (52.7±1.8 counts/min) [F(1,89)=226.8, p<0.01].  
 
Conditioning Trial Activity 
Figure 3 depicts mean (±SEM) activity counts during CS+ and CS- conditioning sessions 
across conditioning trials 1-4, collapsed across sex because no main effect or three way 
interaction with this factor was found.  Alcohol produced locomotor activation on CS+ trials 
compared to CS- trials.  In addition, alcohol-stimulated locomotor activity increased across trials 
indicating that sensitization to the locomotor activating effects of alcohol occurred.  Overall 
analysis of the data (Sex x Conditioning Session Type x Trial) yielded main effects of 
Conditioning Session Type [F(1,88)=958.7, p<0.001] and Trial [F(3,264)=7.0, p<0.001], and Sex 
x Conditioning Session Type [F(1,88)=22.1, p<0.01], Sex x Trial [F(3,264)=3.3, p<0.05] and 
Conditioning Session Type x Trial [F(3,264)=28.9, p<0.001] interactions.  Follow-up one-way 
ANOVAs of Trial within each conditioning session type indicated an increase in activity across 
CS+ conditioning sessions [F(3,267)=2.9, p<0.05] and a decrease in activity across CS- 
conditioning sessions [F(3,267)=75.7, p<0.001]. 
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Table 1 shows the mean (±SEM) time on the CS+ floor (sec/min) in each LY2183240 dose 
group during the first 30 min of the pre-test and post-tests.  Analysis of raw post-test scores 
without reference to pre-test scores did not yield a significant main effect of or interaction with 
Dose Group.  Evidence for place conditioning was further assessed by calculating within-subject 
difference scores that reflect change in the amount of time spent on the CS+ floor during the 
post-test relative to the amount of time spent on the CS+ floor during the pre-test.  Figure 4 
shows place conditioning data for each LY2183240 dose group.  Each preference test is 
depicted separately even though preference remained relatively constant across the three tests, 
as supported by the lack of statistical interactions with the repeated measures Test Day factor 
(see below).   
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Table 1. Average time (sec/min) spent on the alcohol-paired (CS+) floor in HAP mice  
 
   First 30 min                                                   Last 30 min    
 
                                 Pretest      Test 1      Test 2      Test 3         Pretest      Test 1      Test 2      Test 3           
___________________________________________________________________________________ 
 
Vehicle (n=30)        30.8±1.3  40.5±2.0  36.5±2.1  36.7±2.2        29.6±2.2   38.2±2.6   35.3±3.1   35.9±2.9 
 
10 mg/kg (n=30)     29.4±0.9  43.8±1.6  37.7±2.2  38.1±1.4        26.2±2.1   41.9±2.4   40.6±2.6   38.8±2.7 
 
30 mg/kg (n=30)     29.1±1.1  41.8±2.2  36.7±2.4  39.9±1.9        25.8±2.1   43.1±2.5   39.9±2.9   39.3±2.9 
___________________________________________________________________________________ 
 
Alcohol-induced CPP was increased during the last 30 min of the preference tests in both 
the 10 and 30 mg/kg LY2183240 dose groups.  Initial analysis of the data was conducted using 
a five-way ANOVA [Dose Group x Sex x Conditioning Subgroup x Test Day x Time (first 30 min 
and last 30 min)] with repeated measures on the Test Day factor to determine if preference 
changed over the course of repeated testing in the presence and absence of LY2183240.  This 
analysis revealed main effects of Test Day [F(2,156)=7.6, p<0.01] and Time [F(1,78)=5.5, 
p<0.05], a Conditioning Subgroup x Test Day interaction [F(2,156)=6.2, p<0.01], and a Dose 
Group x Conditioning Subgroup x Test Day x Time interaction very close to significance [F(4, 
156)= 2.4, p=0.055].  Follow up ANOVAs (Dose Group x Conditioning Subgroup x Test Day) of 
the four-way interaction were conducted separately for the first 30 and last 30 min of the 
preference test.  For the first 30 min analysis, the ANOVA showed a main effect of Test Day 
[F(2,168)=16.3, p<0.001] and a Conditioning Subgroup x Test Day interaction [F(2,168)=8.3, 
p<0.001].  For the last 30 min analysis, the ANOVA showed a main effect of Dose Group 
[F(2,84)=3.2, p<0.05] and a Conditioning Subgroup x Test Day interaction F(2,168)=3.8, p<0.05.  
As can be seen in Figure 4, the main effect of Dose Group can be accounted for by an increase 
in alcohol-induced CPP in both the 10 and 30 mg/kg groups compared to the vehicle group 
during each of the three preference tests.  Follow up analyses of Dose Group using Tukey’s 
multiple comparison test indicated that the 30 mg/kg dose of LY2183240 produced a greater 
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enhancement of alcohol induced CPP (vehicle vs. 10 mg/kg groups: p=0.098; vehicle vs. 30 
mg/kg groups: p=0.062).   
                  Preference Test 1:  LY2183240 pretreatment









              Preference Test 2:  LY2183240 pretreatment





Preference Test 3:  Drug-free





































































Activity During Post-tests 
Test activity data were analyzed using a three-way ANOVA (Dose Group x Sex x Test Day x 
Time).  The analysis yielded main effects of Test Day [F(2,168)=6.6, p<0.01] and Time 
[F(1,84)=466.3, p<0.001] and Dose Group x Time [F(2,84)=4.4, p<0.05] and Test Day x Time 
[F(2,168)=3.2, p<0.05] interactions.  The Dose Group x Time interaction was further examined 
with one-way ANOVAs of Dose Group for the first and last 30 min of the test sessions 
(collapsed across the three tests) but these analyses showed no significant effect of Dose 
Group.  Mean (±SEM) activity counts during the first and last 30 min of the preference tests, 
respectively, were 64.3±1.8 and 43.2±1.9 for test 1, 64.0±1.7 and 38.8±2.1 for test 2, and 
60.6±1.5 and 37.2±1.9 for test 3.  These analyses indicate that the observed effects of 
LY2183240 on the expression of CPP are not related to drug-induced changes in locomotor 
activity during test sessions.   
 
Experiment 3: Effects of LY2183240 on Limited-access Alcohol Drinking 
On the first day of the 2-hr limited-access procedure, mean (±SEM) body weights were 
26.6±0.4 g for male and 22.6±0.5 g for female mice.  A one-way ANOVA yielded a main effect 
of Sex [F(1,41)=41.2, p<0.01; male>female].  
Figure 5 shows alcohol (g/kg) and total fluid (ml/kg) intake during the acquisition phase 
averaged across 2-day blocks.  Sex x Block ANOVAs indicated that alcohol intake and total fluid 
intake did not significantly change during the acquisition phase. 
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Figure 6a shows alcohol (g/kg) intake during the 2 hrs of limited-access on both drug 
days.  LY2183240 did not significantly alter alcohol intake (g/kg) on either drug testing day.  A 
repeated measures ANOVA (Dose Group x Sex x Test Day) yielded no effects of LY2183240 on 
alcohol intake during the 2 hrs of limited-access, but a significant Dose Group x Test Day 
interaction [F(2,37)=3.0, p<0.05] was found during the first 30 min of the 2-hr drinking session.  
Follow up ANOVAs of Dose Group within each test day yielded no significant effects (data not 














































































Pearson’s product moment correlation indicated that total alcohol intake (g/kg) during the 
final drinking session was significantly correlated with BAC (r2=0.77, p<0.01).  LY2183240 did 
not affect alcohol metabolism in HAP mice based on the ANOVA (Dose Group x Sex) of BAC, 
taken at the end of the final 2-hr drinking session, that yielded no significant main effects or 
interactions. 
Figure 6b shows total fluid (ml/kg) intake during the 2-hr limited-access sessions on both 
drug days.  LY2183240 had no effect on total fluid intake, which was stable across drug testing 
days.  Repeated measures ANOVA (Dose Group x Sex x Test Day) on total fluid intake after 
both the 30 min and 2-hr time points yielded only a Dose Group x Sex x Test Day interaction 
[F(2,37)=3.6,p<0.01] for total fluid (ml/kg) intake during the first 30 min of limited-access but 
follow-up lower order ANOVAs yielded no significant effects.   
 
Discussion 
The goal of the present study was to assess the effects of a novel EC uptake inhibitor, 
LY2183240, on anxiety- and alcohol-seeking behaviors in selectively bred high alcohol 
preferring mice.  LY2183240 produced anxiolytic-like effects using the FPS procedure and also 
increased alcohol-seeking behavior in the CPP procedure.  There were no significant effects of 
LY2183240 on alcohol drinking behavior.  The effects of LY2183240 appear to be selective for 
conditioned behaviors because LY2183240 did not alter unconditioned startle responses or 
general locomotor activity.  Furthermore, LY2183240 did not alter the expression of FPS in LAP 
mice suggesting that the anxiolytic effect of LY2183240 may be selective for mice with a genetic 
propensity toward greater anxiety-related behavior.  These findings suggest that LY2183240 
may influence memory-related processes that regulate the expression of conditioned fear and 
conditioned alcohol reward behavior in HAP mice.  
It is well-established that the ECS plays an important role in regulating memory-related 
processes such as extinction and reconsolidation (see reviews by Diergaarde et al. 2008; Lutz, 
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2007).  Extinction is a process in which new learning is thought to inhibit the expression of a 
conditioned response (Konorski, 1967; Rescorla, 2001).  On the other hand, reconsolidation of a 
memory may act to stabilize a conditioned response (Przybyslawski and Sara, 1997; Rudy et al. 
2006).  Although the conditions under which one process may predominate over the other are 
still a matter of debate, it is generally thought that a brief re-exposure to conditioned cues leads 
to reconsolidation whereas a longer re-exposure to the conditioned cues leads to extinction 
(Pedreira and Maldonado, 2003).  It has also been suggested that the two processes may 
compete depending on the behavioral testing conditions (see review by Eisenhardt and Menzel, 
2007).  The current studies were not specifically designed to differentiate between effects of 
LY2183240 on reconsolidation vs. extinction; however, our data provide some clues as to how 
LY2183240 may affect these memory-related processes (discussed below).  
Results of several prior studies have shown that administration of AEA transport 
inhibitors (Bitencourt et al. 2008; Chhatwal et al. 2005; Pamplona et al. 2008; Resstel et al. 
2008) or AEA itself (Resstel et al. 2008) facilitates the extinction of learned fear responses in 
models of fear conditioning.  Consistent with these prior reports, we found that the higher dose 
of LY2183240 (30 mg/kg) significantly reduced the expression of FPS, but only after a second 
FPS test.  This result is comparable to that reported by Chhatwal et al. (2005) who found similar 
effects of the EC uptake inhibitor, AM404, on conditioned fear using the FPS model.  In that 
study, administration of AM404 prior to extinction training (re-exposure to conditioned light cues) 
reduced the subsequent expression of FPS but had no effect on FPS when extinction training 
was omitted.  This result is analogous to that seen in the current study where LY2183240 did 
not alter FPS expression during the first test.  Thus, the first FPS test may have served as an 
extinction session that led to the nearly complete elimination of FPS seen during the second 
FPS test in the 30 mg/kg LY2183240 dose group.  We interpret these data to suggest that 
sustained activation of the ECS via LY2183240 during repeated exposure to conditioned fear 
stimuli may be necessary to facilitate the extinction of learned fear responses.  However, this 
23 
interpretation should be taken with caution as the FPS procedure used here was not specifically 
designed to assess extinction.  Additional studies will also be important to examine whether the 
effects of LY2183240 on FPS expression persist in the absence of the drug.  
It has previously been reported that alcohol produces weaker CPP in CB1 receptor 
knockout mice compared to their wild-type controls (Houchi et al. 2005; Thanos et al. 2005), 
indicating that CB1 receptors modulate the rewarding effects of alcohol and the acquisition of 
alcohol-induced CPP.  The present data are the first to show that pharmacological modulation of 
the ECS influences the expression of alcohol-induced CPP in mice.  Consistent with our 
hypothesis, LY2183240 enhanced the expression of alcohol-induced CPP.  This result suggests 
that LY2183240 may increase the incentive salience of conditioned floor cues associated with 
alcohol reward and facilitate approach behavior during the place preference test.  The effect of 
LY2183240 on CPP expression was moderate in size and was most prominent during the last 
30 min of the preference tests.  The fact that this effect emerged during the last half of the 
preference tests and was maintained to the same degree on the third preference test in the 
absence of the drug, suggests that exposure to the pharmacological effects of LY2183240 
together with alcohol conditioned cues may strengthen the alcohol reward-related memory.  
Such an interpretation could be consistent with a reconsolidation hypothesis if one considers 
that the first 30 min of the preference test might be analogous to a relatively brief period of re-
exposure to the conditioned cues, as has been suggested for reconsolidation to occur (e.g., 
Przybyslawski and Sara, 1997).  In this case, exposure to the conditioned cues at the start of 
the preference test, along with LY2183240 pretreatment, may have served to “reactivate” and 
subsequently strengthen the alcohol reward memory.  There is emerging evidence that the ECS 
may influence memory reconsolidation (see review by Diergaarde et al. 2008), including drug 
reward-related memories.  For example, Yu and colleagues (2009) recently reported that the 
CB1 receptor antagonist SR141716A (rimonabant) interfered with the reconsolidation of 
methamphetamine-induced CPP.  Of course, this idea remains speculative in the absence of a 
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defined procedure to specifically test memory reconsolidation in the present study.  An 
alternative interpretation of the CPP data is that LY2183240 reduced a conditioned aversion to 
alcohol which increased the magnitude of alcohol-induced CPP.  This idea is relevant to the 
extent that expression of the overall magnitude of the CPP may be moderated to some degree 
by conditioned aversive motivational effects of alcohol in addition to rewarding effects of alcohol 
(see Cunningham et al., 2003 for an experimental analysis and discussion of this issue).  Future 
place or taste aversion studies could be conducted to test whether LY2183240 alters the 
expression of conditioned aversion to alcohol.   
Taken together, results of the FPS and CPP studies suggest that ECS activation by 
LY2183240 seems to influence the expression of learned behaviors, but the direction of the 
effect depends on the type of learning involved.  LY2183240 attenuated the conditioned 
response produced by an aversive shock stimulus and enhanced the conditioned response 
produced by a rewarding alcohol stimulus, perhaps through effects on extinction or memory 
reconsolidation.  The apparent diversity of LY2183240’s effects on aversive and appetitive 
behaviors is somewhat akin to reported findings in the literature in which ECS drugs have been 
studied.  For example, rimonabant disrupted extinction of aversive conditioned responses in 
fear-conditioning and passive avoidance tasks but had no effect on learned responses in an 
appetitively motivated food task (Niyuhire et al. 2007).  Rimonabant has also been shown to 
interfere with extinction learning in an aversive but not appetitive Barnes maze conditioning 
procedure (Harloe et al. 2008).  In addition, Manwell et al. (2009) reported that the EC uptake 
inhibitor, URB597, facilitated extinction, whereas rimonabant inhibited extinction, of conditioned 
place aversion to naloxone-precipitated morphine withdrawal but neither drug affected 
morphine-induced CPP.   
The ECS has very diverse roles in the regulation of neuronal function and behavior (see 
review by Kano et al. 2009).  It is likely that the different effects of EC drugs on aversive vs. 
appetitive conditioned behavior seen in the present study and in prior reports are largely 
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attributable to differential modulation of EC function in discrete brain regions involved in 
memory, anxiety, and drug reward.  For example, the amygdala is a brain structure critically 
involved in auditory fear conditioned behavior such as FPS (Davis, 2006), and tone 
presentations during conditioned fear extinction trials are associated with elevated levels of ECs 
in the amygdala but not in other brain regions such as the prefrontal cortex (PFC) (Marsicano et 
al. 2002).  ECs regulate neural signaling in reward-related brain regions such as the ventral 
tegmental area and nucleus accumbens (see review by López-Moreno et al. 2008), areas that 
have been specifically implicated in the expression of alcohol-induced CPP in mice (Bechtholt 
and Cunningham, 2005; Gremel and Cunningham, 2008).  Thus, systemic administration of 
LY2183240 may result in different neurochemical and behavioral effects depending on the basal 
or activity-dependent levels of ECs and CB receptor distribution in these various brain regions.    
Inactivation of the ECS by genetic deletion and pharmacological blockade of CB1 
receptors has been shown to reduce alcohol intake (e.g., Cippitelli et al. 2005; Colombo et al. 
2007; Hansson et al. 2007; Hungund et al. 2003), while stimulating the ECS by direct CB1 
activation increases alcohol seeking behavior assessed via operant self-administration (Gallate 
et al. 1999; Hansson et al. 2007) and home-cage, 24-hr, free-access procedures (Colombo et 
al. 2002).  In theory, one would predict that EC uptake inhibitors should have similar effects as 
CB1 receptor direct agonists because enhancing synaptic EC levels should result in greater 
CB1 receptor activation.  However, EC uptake inhibitors have been reported to have 
inconsistent effects on alcohol intake behavior that may be related, in part, to differences in drug 
mechanism of action, drinking procedures, strain, or species.  For example, URB597 has been 
shown to both increase (Hansson et al. 2007) and have no effect (Cippitelli et al. 2008) on 
operant self-administration in Wistar rats.  In studies using home-cage drinking procedures, 
URB597 increased drinking during 8-hr and 24-hr free-access periods in C57BL/6J mice (Vinod 
et al. 2008) and in mice with a 129/SvJ/C57Bl/6J genetic background (Blednov et al. 2007), 
respectively, but did not alter drinking during a 1-hr alcohol access period in selectively bred 
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Marchigian Sardinian alcohol-preferring (msP) rats (Cippitelli et al. 2008).  Another EC uptake 
inhibitor, AM404, reduced operant responding for alcohol in rats, an effect that was not 
mediated through CB1 or CB2 receptors (Cippitelli et al. 2007).  These findings suggest that EC 
uptake inhibitors have unique, yet still poorly understood, pharmacological properties and may 
interact with the ECS or other neurotransmitter systems in diverse ways to affect behavior.   
In contrast to our hypothesis, LY2183240 in the current study did not alter alcohol intake 
in a 2-hr limited access drinking procedure in HAP mice.  This result is consistent with those 
reported by Cippitelli and colleagues (2008) where URB597 had no effect on alcohol intake in 
alcohol preferring msP rats during a 1-hr limited access drinking paradigm.  It should be noted 
that several studies have reported altered ECS function in alcohol-naïve rodents with a genetic 
propensity toward high alcohol preference when compared to their low-alcohol-preferring 
counterparts (Cippitelli et al. 2005; Hansson et al. 2007; Hungund and Basavarajappa, 2000).  
For example, Hansson and colleagues (2007) found decreased CB1 receptor expression in the 
PFC, as well as decreased FAAH expression and higher levels of ECs [1- arachidonoylglycerol 
(AG) and 2-AG, but not AEA], in the alcohol-preferring Alko Alcohol (AA) rat line compared to 
the nonpreferring Alko Non-Alcohol (ANA) rat line.  Thus, altered sensitivity to the effects of EC 
uptake/FAAH inhibitors in animals that differ in genetic predisposition toward alcohol drinking 
may be an important factor that could explain absent or discrepant effects of EC drugs on 
behavior.  We are currently examining whether ECS function differs in selectively bred HAP vs. 
LAP mice.   
CPP is thought to be a useful model for understanding certain learning and memory 
processes and to investigate the role of environmental cues in influencing craving, relapse, and 
alcohol-seeking behavior, whereas oral alcohol intake procedures assess the primary 
reinforcing effects of alcohol via consummatory behavior models (Cunningham et al. 2000).  
Assessments of the relation between alcohol drinking behavior and alcohol-induced CPP using 
pharmacological and genetic manipulations suggest that these two behavioral models seem to 
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tap into similar alcohol-reward related mechanisms, at least in mice (see review by Green and 
Grahame, 2008).  However, there are numerous examples in the literature that also highlight a 
dissociation between alcohol-reward related behavior as measured in CPP (e.g., Chester et al. 
1998; Cunningham et al. 1992; Dickinson et al. 2003; Risinger et al. 1992a; 1992b) vs. oral 
alcohol intake procedures (e.g., Hodge et al. 1997; Kosobud et al. 1988; Ng and George, 1994; 
Samson et al. 1987).  The finding that LY2183240 increased the expression of alcohol-induced 
CPP but did not alter alcohol drinking behavior in the current study provides further support for 
the idea that these two alcohol-reward related behaviors are regulated by different 
neurobiological mechanisms and that LY2183240 may modulate memory mechanisms 
important for the expression of conditioned but not unconditioned alcohol reward behavior.   
Future studies should examine the effects of CB1 receptor antagonists in combination 
with LY2183240 to explore the extent to which the effects of LY2183240 may be mediated 
through CB1 receptor activation.  While the behavioral effects of LY2183240 are likely mediated 
through actions at CB receptors in the brain, it is also possible that other receptors activated by 
the ECs may be involved.  Transient receptor potential V1 receptors are activated by AEA and 
are thought to primarily function in pain and inflammatory responses although a role in mood 
has been suggested (De Petrocellis and Di Marzo, 2009).  The ECs are also agonists at nuclear 
peroxisome proliferator-activated receptors (PPARs).  Physiological actions associated with EC 
action at PPARs include regulation of metabolic functions, pain, and inflammatory processes 
making it unlikely that the effects observed in the present study are associated with activity at 
the PPARs (O'Sullivan, 2007).  Also, the use of a monoacylglycerol lipase inhibitor to selectively 
elevate 2-AG vs. AEA would be useful to further characterize the pharmacological basis for the 
behavioral effects of LY2183240.  Finally, it should be noted that the ECs represent a diverse 
set of lipid signaling molecules and LY2183240 inactivates other serine hydrolases besides 
FAAH (Alexander and Cravatt, 2006); thus, other fatty acid amides or esters besides AEA or 2-
AG may mediate the behavioral effects seen in the present study. 
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In conclusion, selectively bred HAP mice are a unique animal model that represents 
increased genetic risk to develop alcoholism and co-morbid PTSD in humans and provides a 
useful tool to explore pharmacological interventions for these co-morbid disorders.  Here, we 
provide original findings in the HAP model that add to a growing body of literature centered on 
the identification of new therapies for co-morbid disorders.  Results of the present study showed 
that the novel EC uptake inhibitor, LY2183240, decreased FPS and increased alcohol-induced 
CPP in HAP mice.  These data suggest that drugs such as LY2183240 that target the EC 
uptake mechanism may be particularly effective in the treatment of anxiety disorders such as 
PTSD, a disorder which is thought to involve impaired extinction of aversive memories.  
However, cautious interpretation of the present data suggests that LY2183240 or similar drugs 
may not be a useful therapy for individuals with independent or co-morbid alcohol-use disorders.  
This work may ultimately help to identify novel drug treatments to reduce both anxiety and 
alcohol consumption in people with co-morbid disorders and these pharmacological treatment 
strategies may prove to be particularly effective in people who are at increased genetic risk for 
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Figure 1.  Mean (±SEM) %FPS in male and female HAP mice in each LY2183240 dose group 
during the first (Test 1) and second (Test 2) FPS test.  Mice received IP injections of either drug 
(10 mg/kg or 30 mg/kg) or vehicle 30 min before each FPS test, which were given 24 hrs apart. 
*Indicates p<0.05 (10 mg/kg vs. 30 mg/kg); **indicates p<0.01 (0 vs. 30 mg/kg). 
 
Figure 2.  Mean (±SEM) %FPS in male and female LAP mice for each LY2183240 dose group 
during the first (Test 1) and second (Test 2) FPS test.  Mice received IP injections of either drug 
(10 mg/kg or 30 mg/kg) or vehicle 30 min before each FPS test, which were given 24 hrs apart.   
 
Figure 3.  Mean (±SEM) activity counts per minute for male and female HAP mice during CS+ 
and CS- conditioning trials.  
 
Figure 4.  Mean (±SEM) sec per minute (sec/min) on alcohol-paired floor (post-test – pre-test 
difference score) in male and female HAP mice in each LY2183240 dose group during the first 
and last 30 min of each of the three preference tests.  Mice received IP injections of either drug 
(10 mg/kg or 30 mg/kg) or vehicle 30 min before the first two preference tests (top and middle 
panels) and saline injections 30 min before the drug-free preference test (bottom panel).  
*Indicates main effect of Dose Group collapsed across preference tests (p<0.05).  
 
Figure 5.  Mean (±SEM) alcohol (left y-axis; g/kg) and total fluid (right y-axis; ml/kg) intake in 
HAP mice averaged across 2-day blocks during the 8 days of the alcohol acquisition phase.  IP 
saline injections were administered 30 min prior to the 2-hr limited-access sessions on the final 
two days of the acquisition phase (block 4).  
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Figure 6.  Mean (±SEM) alcohol (g/kg; panel a) and total fluid (ml/kg; panel b) intake in HAP 
mice within each LY2183240 dose group during the 2-hr limited access session on the first 
(drug day 1) and second (drug day 2) drug testing days.  Mice received IP injections of either 
drug (10 mg/kg or 30 mg/kg) or vehicle 30 min before access to alcohol and water. 
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Table Legend 
Table 1.  Mean (±SEM) time (sec/min) spent on the alcohol-paired (CS+) floor (sec/min) in each 
LY2183240 dose group during the first and last 30 min of the pre-test and post-tests.  
 
